A new study shows that stem cell therapy may help people suffering heart failure. The clinical trial found that end-stage heart failure patients who were treated with stem cells harvested from their own bone marrow, had 37 percent fewer cardiac events than those who received the placebo.
For the last 15 years, people have been debating stem cell therapy and its benefits. While the new 2016 findings are promising — and hopefully, improve the levels of heart performance and efficiency — further long-term data still needs to be seen.
During heart failure, a damaged heart can no longer pump blood the way a normal heart can. This potentially deadly disease affects roughly 5.7 Americans, according to the American Heart Association.
The new study included 126 heart failure patients. 60 patients received the stem cell treatment, and the other 66 received a placebo.
During the course of one year, four percent of the stem cell therapy patients had died and about 52 percent of them had been hospitalized for heart failure.
However, that was an improvement compared to the placebo, where eight percent of patients had died and more than 82 percent of them ended up in the hospital, concluded Dr. Amit Patel, director of Cardiovascular Regenerative Medicine at the University of Utah School of Medicine in Salt Lake City.
If further studies are successful, stem cell therapy may one day offer a different form of treatment for end-stage heart failure.
The study was published last April in The Lancet journal.
For more information, visit the American Heart Association and/or The American Academy of Family Physicians: https://familydoctor.org/familydoctor/en/diseases-conditions/heart-failure.printerview.all.html
Comments are closed.